NEXTBio Capital Management LP
An institutional investment manager in AUSTIN, TX. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2038158.
- Reported value$217.4m
- Positions22
Holdings: 22 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 26.9 | 12.4% | 219,333 | Reduced−10,286 | |
| Shattuck Labs IncSTTK | COM | 82024L103 | 25.9 | 11.9% | 3,727,348 | Added+577,441 | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 25.1 | 11.6% | 1,775,759 | Reduced−245,648 | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 16.8 | 7.7% | 312,496 | Added+179,257 | |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 16.4 | 7.5% | 889,164 | Reduced−110,803 | |
| Rhythm Pharmaceuticals IncRYTM | COM | 76243J105 | 14.6 | 6.7% | 131,758 | Added+5,680 | |
| Palvella Therapeutics Inc NePVLA | COM | 697947109 | 13.7 | 6.3% | 89,909 | Added+7,223 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 11.1 | 5.1% | 183,225 | Unchanged | |
| Zenas Biopharma IncZBIO | COM | 98937L105 | 10.8 | 5.0% | 426,736 | Unchanged | |
| Oric Pharmaceuticals IncORIC | COM | 68622P109 | 7.6 | 3.5% | 706,124 | Added+182,505 | |
| Inventiva SAIVA | ADS | 46124U107 | 6.8 | 3.1% | 1,787,984 | Added+454,500 | |
| Crescent Biopharma Inc. | COM | G2545C104 | 6.7 | 3.1% | 372,856 | Unchanged | |
| Vaxcyte IncPCVX | COM | 92243G108 | 6.2 | 2.9% | 107,223 | Added+12,000 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 5.1 | 2.3% | 131,075 | Reduced−113 | |
| Verastem IncVSTM | COM NEW | 92337C203 | 5.0 | 2.3% | 1,306,800 | Unchanged | |
| Disc Medicine IncIRON | COM | 254604101 | 3.9 | 1.8% | 52,655 | Unchanged | |
| Pharvaris N V | COM | N69605108 | 3.7 | 1.7% | 108,055 | New+108,055 | |
| ZAI Lab LtdZLAB | ADR | 98887Q104 | 3.5 | 1.6% | 183,362 | Unchanged | |
| Bioage Labs IncBIOA | COM | 09077V100 | 2.5 | 1.1% | 100,732 | New+100,732 | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 2.2 | 1.0% | 68,249 | New+68,249 | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 1.6 | 0.7% | 119,063 | Reduced−65,000 | |
| Adicet Bio IncACET | COM NEW | 007002207 | 1.4 | 0.6% | 157,827 | Unchanged |
Sold out: 5 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Compass Therapeutics IncCMPX | COM | 20454B104 | 0.0 | 0.0% | 0 | Sold out−848,204 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−131,796 | |
| Oculis Holding AG | ORDINARY SHARES | H5870P102 | 0.0 | 0.0% | 0 | Sold out−149,592 | |
| Summit Therapeutics IncSMMT | COM | 86627T108 | 0.0 | 0.0% | 0 | Sold out−89,717 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−604,534 |
Source: SEC EDGAR, Form 13F-HR, accession 0001172661-26-003533 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.